Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimization of once-daily insulin glargine 300 IU/ml in type 1 diabetes patients uncontrolled on twice-daily basal insulin
2015-001186-46Phase 4Completed
- Sponsor
- Sanofi
- Start
- Jul 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of insulin glargine in diabetes mellitus type 1 (T1D), sponsored by Sanofi. Primary endpoint: Mean HbA1c change from baseline to Week 28. Started Jul 2015; status: completed.
02
Drugs
insulin glargine
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2015-001186-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001186-46.